Avalo Therapeutics, Inc. (AVTX) Stock Forecast Oct. 15, 2026

Our AI ranks Avalo Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Avalo Therapeutics, Inc. is a small-cap company with a market capitalization of $635M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its Net Margin of -56685.3% is the lowest of the 33 peers that report one.

For AVTX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 29.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.4%, sell < -0.7%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)

All daily signals →